ÂÜÀòÂÒÂ×

Dylan Morris is a Managing Director at Insight. He joined the firm in 2021 to focus on investments in computational biology. Dylan was previously a general partner at CRV, where he built the bioengineering practice, leading the firm’s investments in Dyno Therapeutics, Recursion Pharmaceuticals, and Plexium, among others. Prior to CRV, Dylan invested at Innovation Endeavors, Eric Schmidt’s early-stage venture capital firm, where he drove investments in companies operating at the intersection of data science and life science. Before becoming an investor, Dylan co-founded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Prior to that, he conducted graduate research in biochemistry and molecular biophysics at Caltech, where he co-authored multiple peer-reviewed publications. Dylan received his A.B. in Computer Science from Harvard University.